• news.cision.com/
  • CS MEDICA A/S/
  • CS MEDICA Initiates Registration of 6 Medical Devices in Malaysia through their Joint Venture, Rongshi MEDICA Co. Ltd.
English

CS MEDICA Initiates Registration of 6 Medical Devices in Malaysia through their Joint Venture, Rongshi MEDICA Co. Ltd.

Report this content

CS MEDICA ("CS MEDICA" or "the Company") is pleased to announce the initiation of the registration process for its six medical devices in Malaysia. This  initiative is undertaken in partnership with Rongshi MEDICA Co. Ltd.("RongShi Medica" or the "Joint Venture").

Following our invastigation into the Asian market space, while commiting to regulatory compliance and market exploration, CS MEDICA and Rongshi Medica Co. Ltd. have embarked on the journey of registering six medical devices in Malaysia with legal representation provided by Andaman Medical, Malaysia. Rongshi Medica Co. Ltd. And CS MEDICA have already signed the contract with Andaman Medical and can hereby initiate the registration immediately. 

Jason, Managing Director, RongShi MEDICA states:

"Our research shows that Sativex, a cannabis prescription medicine, was approved by the Malaysian FDA in 2014. This makes registering our six medical devices easier, which we expect to classify as Class I & II according to Malaysian FDA regulations. Given CS MEDICA's financial situation, we cover the registration costs and aim to enter the Malaysian market as quickly and successfully as possible to expand into Asia."

Lone Henriksen, CEO at CS MEDICA supports:

"Following a highly successful presence at CPHI in Guangzhou and fruitful discussions on our shared future, we are delighted to embark on the registration process in Malaysia. It marks a significant step forward in our partnership and underscores our immense potential in cooperation within the Asian market".


For more information about CS MEDICA, please contact:
Lone Henriksen, CEO
Phone: + (45) 71 20 30 47
Email: lh@cs-medica.com
Website: https://www.cs-medica.com/

CS MEDICA A/S is a Danish-based MedTech company operating globally within research, development, manufacturing, commercializing, and a part of the pharmaceutical industry. The company combines science and nature with the purpose of creating products for a better every day by using modern technology to research and utilize different compounds found in the cannabis plant. CS MEDICA offers efficient, safe OTC alternative treatments with CBD for autoimmune and stress-related disorders under the trademark CANNASEN® or own-label options. 

The company is listed on Spotlight Stock Market in Stockholm (symbol: “CSMED”). For more information, visit cs-medica.com, and LinkedIn.

Tags:

Asia Malaysia medical device CBD market expansion cannabisindustri

Subscribe

Media

Media

Documents & Links

Quotes

Our market research in Asia, has revealed that the Malaysian FDA approved the cannabis prescription medicine Sativex in 2014. This significantly streamlines the registration process for our six medical devices, which we expect to classify as Class 1 & 2, aligning with Malaysian FDA regulations. In light of CS MEDICA's financial situation, we are pleased to cover all registration costs. We anticipate a swift market entry in Malaysia and a successful venture into the Asian market.
Jason, Managing Director, Rongshi Medica Co. Ltd.
Following successful joint participation with our Joint Venture partner Rongshi Medica at CPHI in Guangzhou, we are delighted to embark on the registration process in Malaysia. This marks a significant step forward in our partnership and underscores the immense potential we see in our cooperation within the Asian market.
Lone Henriksen, CEO at CS MEDICA